Skip to content
S6542Senate2023-2024 SessionSame asA7338

Expand Newborn G6PD Screening

Official title

“Relates to newborn screening for glucose-6-phosphate dehydrogenase deficiency”

Sponsor Gustavo RiveraSD-33+1 co-sponsorAffects Finance
Status
Vetoed
Impact
6/10
Moderate
Outcome
Vetoed

Bill progress

Vetoed

What's happening

The bill requires universal newborn screening for glucose-6-phosphate dehydrogenase deficiency, removing previous restrictions based on risk factors or symptoms.

Why it matters

  1. Expanding universal screening. By removing prior requirements that limited testing to newborns with symptoms or certain risk factors, the bill ensures all newborns are tested for G6PD deficiency, allowing earlier detection and intervention regardless of background.

  2. Reducing missed diagnoses. Universal screening helps catch cases in babies who might not fit traditional risk profiles or show obvious symptoms at birth, preventing potential complications from going undiagnosed.

  3. Promoting health equity. The shift away from ancestry- or symptom-based criteria addresses potential biases and ensures all newborns, regardless of race or family history, receive equal access to potentially life-saving screening.

  4. Supporting preventive care. Early identification of G6PD deficiency can help families and healthcare providers avoid triggers and manage the condition proactively, potentially reducing hospitalizations and long-term health issues.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Expand Newborn G6PD Screening

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Gustavo Rivera

Senator · Senate District 33

Chair, Health

1 Co-sponsor

History

  1. Vetoed memo.143
  2. Delivered to governor
  3. Returned to senate
  4. Passed assembly
  5. Ordered to third reading rules cal.866
  6. Substituted for A7338
  7. Referred to ways and means
  8. Delivered to assembly
  9. Passed senateVote 61–0
  10. Ordered to third reading cal.1527
  11. Committee discharged and committed to rules
  12. Reported and committed to finance
Show 1 earlier action
  1. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A7338Assembly

Expand Newborn G6PD Screening

Assembly Floor Calendar · Sponsor Amy Paulin

Impact 6 · Moderate0% to pass

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

6542

2023-2024 Regular Sessions

IN SENATE

April 26, 2023

Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to newborn screening for glucose-6-phosphate dehydrogenase deficiency

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph (j) of subdivision 1 of section 2500-a of the public health law, as amended by chapter 70 of the laws of 2022, is amended to read as follows:

(j) Glucose-6-phosphate dehydrogenase deficiency [using a quantitative enzymatic test or other diagnostic test in cases where: the newborn infant presents with hemolytic anemia, hemolytic jaundice, or early-onset increasing neonatal jaundice, that is, jaundice (bilirubin level greater than fortieth percentile for age in hours) persisting beyond the day of birth through the week after birth; the newborn infant has been admitted to the hospital for jaundice following birth; or the biological parent of the newborn infant indicates a family, racial, or ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including having significant African, Asian, Mediterranean, or Middle Eastern ancestry].

§ 2. This act shall take effect immediately.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD10869-02-3

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to newborn screening for glucose-6-phosphate dehydrogenase deficiency

Purpose

Requires glucose-6-phosphate dehydrogenase deficiency testing for all newborns.

Summary of specific provisions

Section 1 amends paragraph (j) of subdivision 1 of section 2500-a of the public health law by removing the requirements that limit testing of glucose-6-phosphate dehydrogenase deficiency in newborns.

Section 2 provides the effective date

Justification

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic enzyme disorder that affects the functioning of red blood cells and has the potential to cause attacks of acute hemolytic anemia, severe neonatal jaundice, and kernicterus, which is caused by high levels of bilirubin and can affect brain development. In the most severe cases, untreated G6PD deficiency leads to permanent brain damage and sometimes death.

Under current law, there are certain conditions for newborns to qualify for the G6PD screening. The law requires newborns to already be showing symptoms of hemolytic anemia, severe jaundice, or be at an ethnic risk by having African, Asian, Mediterranean, or Middle Eastern ancestry. Waiting until symptoms are present before screening for G6PD deficiency, can lead to severe complications for the baby. When checking a newborn for G6PD, bilirubin levels can also be checked before it reaches harmful levels. Currently, bilirubin levels aren't checked until after the damage has been done. Additionally, by separating this screening out from other newborn screenings the process to perform the task is made more complicated, and it is more invasive to the infant-patient. With New York being such a diverse state, G6PD should be a requirement for newborn screening regardless if symptoms are present or not. Removing the preconditions requirement for G6PD testing will ensure that newborns receive timely treatment that is needed to avoid further complications.

Legislative history

New legislation.

Fiscal implications

Minimal.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.